
Genitourinary Cancers
Latest News
Video Series

Latest Videos
Shorts



Podcasts
CME Content
More News

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

Ahead of the 2026 AUA Annual Meeting, GU cancer experts highlighted the abstracts that they are anticipating the most.

We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.

Simlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.

Bradley McGregor, MD, discusses the end points that will be evaluated in the phase 3 STRIKE trial of adjuvant tivozanib plus pembrolizumab in high-risk RCC.

Bradley McGregor, MD, discusses the rationale of the STRIKE trial of tivozanib plus pembrolizumab in RCC.

Nivolumab plus cabozantinib was safe and active for the real-world frontline treatment of patients with advanced RCC.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

Adanma Ayanambakkam, MD, MS, discusses the safety profile of darlifarnib plus cabozantinib in ccRCC.

Adanma Ayanambakkam, MD, MS, discusses efficacy data from the phase 1a/1b FIT-001 trial.

Mina M. Fam, MD, and Bradley McGregor, MD, discuss the treatment landscape of testicular cancer during Testicular Cancer Awareness Month.

The top 5 OncLive TV videos of the week cover insights in head and neck cancer, esophageal cancer, renal cell carcinoma, and breast cancer.

The FDA grants priority review to enfortumab vedotin-ejfv sBLAs in MIBC, the review period for subcutaneous isatuximab BLA in myeloma has been extended, and more.

Adanma Ayanambakkam, MD, MS, discusses the mechanism of action of darlifarnib in ccRCC.

Fecal microbiota transplantation extended median PFS with first-line pembrolizumab plus axitinib in metastatic RCC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Darlifarnib plus cabozantinib showed preliminary activity and safety across dose levels in cabozantinib-treated ccRCC.

Pembrolizumab plus lenvatinib and belzutifan, as well as pembrolizumab/quavonlimab plus lenvatinib, did not extend OS or PFS in first-line ccRCC.

Taigo Kato, MD, PhD, discusses the use of ctDNA-guided therapy in patients with RCC.

The top 5 OncLive TV videos of the week cover insights in mantle cell lymphoma, endometrial cancer, salivary gland cancer, myeloproliferative neoplasms, and renal cell carcinoma.

In case you missed any, check out our recap of the episodes of OncLive On Air that aired in March 2026.

Cabozantinib was active with no new safety signals in second-line advanced RCC after treatment with frontline checkpoint inhibitor–based therapy.
































































